20-F: Legend Biotech Details Securities Registration in 20-F Filing

Legend Biotech's 20-F filing details the registration of its American depositary shares (ADS) and ordinary shares on the Nasdaq Global Select Market as of December 31, 2023, along with comprehensive information on share structure, shareholder rights, and corporate governance.

Summary

• Legend Biotech Corporation had its American depositary shares (ADS) and ordinary shares registered on the Nasdaq Global Select Market as of December 31, 2023.
• The company's authorized share capital is $200,000 divided into 2,000,000,000 shares.
• As of December 31, 2023, Legend Biotech had 363,822,069 ordinary shares issued and outstanding.
• Each ADS represents two ordinary shares.
• Shareholders do not have preemptive purchase rights.
• The board of directors can fix the rights, preferences, privileges, and restrictions of up to 1,000,000 other shares, including preference shares.
• Shareholders are entitled to dividends as declared by the board of directors.
• Each ordinary share carries one vote.
• The company's objects are unrestricted, allowing it to carry out any object not prohibited by Cayman Islands law.
• The company is an exempted company with limited liability under Cayman Islands law.
• Share transfers are subject to board approval and certain conditions.
• The board can issue additional ordinary and preference shares.
• The company's memorandum and articles of association contain anti-takeover provisions.
• Cayman Islands law differs from U.S. corporate law in areas such as mergers, shareholder suits, and fiduciary duties.
• As of December 31, 2023, options covering 6,366,538 ordinary shares were outstanding with a weighted-average exercise price of $9.33 per share.
• As of December 31, 2023, there were restricted stock units outstanding representing 4,948,956 ordinary shares upon vesting.
• JPMorgan Chase Bank, N.A. is the depositary for the ADSs.
• The depositary will distribute dividends and other distributions on the underlying shares to ADR holders.
• ADR holders may instruct the depositary how to exercise voting rights for the shares underlying their ADSs.
• The deposit agreement contains limitations on the obligations and liability of the depositary and the company.
• ADR holders and beneficial owners agree to comply with disclosure requirements and ownership limitations related to deposited securities.

Sentiment

Score: 5

Explanation: The document is neutral in sentiment as it is a factual description of the company's share structure and governance. It does not express any positive or negative opinions about the company's prospects.

Positives

• Shareholders are entitled to dividends as declared by the board of directors.
• Each ordinary share carries one vote.
• The company's objects are unrestricted, allowing it to carry out any object not prohibited by Cayman Islands law.
• The company is an exempted company with limited liability under Cayman Islands law.

Negatives

• The issuance of other shares, including potentially preference shares, could adversely affect the voting power of holders of ADSs and the likelihood that such holders will receive dividend payments and payments upon liquidation.
• Some provisions of our Memorandum and Articles may discourage, delay or prevent a change of control of our company or management that shareholders may consider favorable.

Risks

• The issuance of other shares, including preference shares, could have the effect of delaying, deferring, or preventing a change of control or other corporate action.
• Holders of ADSs may not be entitled to a jury trial with respect to claims arising under the deposit agreement, which could augur less favorable results to the plaintiff(s) in any such action.
• There is no guarantee that you will receive voting materials in time to instruct the depositary to vote and it is possible that you, or persons who hold their ADSs through brokers, dealers or other third parties, will not have the opportunity to exercise a right to vote.

Future Outlook

The document does not contain any specific forward-looking statements or guidance regarding future financial performance or business strategy beyond the details of the share structure and shareholder rights.

Industry Context

This announcement is a standard securities registration document and does not provide specific insights into the competitive landscape or industry trends beyond Legend Biotech's own corporate structure and governance.

Comparison to Industry Standards

• The document does not provide a comparison of Legend Biotech's results to global benchmarks or comparable companies.
• It primarily focuses on the company's share structure, shareholder rights, and corporate governance within the legal framework of the Cayman Islands.

Stakeholder Impact

• Shareholders: Details their rights, voting power, and potential dilution.
• Employees: Outlines share option and restricted stock unit schemes.
• Customers: No direct impact.
• Suppliers: No direct impact.
• Creditors: No direct impact.

Key Dates

Keywords

ordinary shares, ADS, securities, shareholders, Cayman Islands, Legend Biotech, preference shares, voting rights, dividends, Nasdaq